The most comprehensive approach to TCR therapeutics
Immatics is leveraging two TCR discovery engines, XPRESIDENT and XCEPTOR, for a 360º approach to the development of TCR-based therapeutics. The company developed two technology platforms: i) ACTengine for TCR T cell therapies, and ii) TCER for TCR bispecifics. Moreover, early-stage allogeneic techn
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.